334 related articles for article (PubMed ID: 27339764)
21. NMDA receptors in hyperammonemia and hepatic encephalopathy.
Llansola M; Rodrigo R; Monfort P; Montoliu C; Kosenko E; Cauli O; Piedrafita B; El Mlili N; Felipo V
Metab Brain Dis; 2007 Dec; 22(3-4):321-35. PubMed ID: 17701332
[TBL] [Abstract][Full Text] [Related]
22. Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes.
Oeltzschner G; Butz M; Baumgarten TJ; Hoogenboom N; Wittsack HJ; Schnitzler A
Metab Brain Dis; 2015 Dec; 30(6):1429-38. PubMed ID: 26359122
[TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Alexeeva O; Zupanets IA; Grinevich V; Baranovsky A; Dudar L; Fadieienko G; Kharchenko N; Klaryts'ka I; Morozov V; Grewal P; McCashland T; Reddy KG; Reddy KR; Syplyviy V; Bass NM; Dickinson K; Norris C; Coakley D; Mokhtarani M; Scharschmidt BF;
Hepatology; 2014 Mar; 59(3):1073-83. PubMed ID: 23847109
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Rahimi RS; Safadi R; Thabut D; Bhamidimarri KR; Pyrsopoulos N; Potthoff A; Bukofzer S; Bajaj JS
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2626-2635.e7. PubMed ID: 33069881
[TBL] [Abstract][Full Text] [Related]
25. New strategies for treating hepatic encephalopathy.
Gómez-Gutiérrez C; Manzano-Robleda MC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2014; 13(3):409-11. PubMed ID: 24756021
[No Abstract] [Full Text] [Related]
26. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Stravitz RT; Gottfried M; Durkalski V; Fontana RJ; Hanje AJ; Koch D; Hameed B; Ganger D; Subramanian RM; Bukofzer S; Ravis WR; Clasen K; Sherker A; Little L; Lee WM;
Hepatology; 2018 Mar; 67(3):1003-1013. PubMed ID: 29080224
[TBL] [Abstract][Full Text] [Related]
27. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
28. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
[TBL] [Abstract][Full Text] [Related]
29. Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.
Rahimi RS; Rockey DC
Clin Liver Dis; 2015 Aug; 19(3):539-49. PubMed ID: 26195207
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide in hepatic encephalopathy and hyperammonemia.
Rao VL
Neurochem Int; 2002; 41(2-3):161-70. PubMed ID: 12020616
[TBL] [Abstract][Full Text] [Related]
31. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.
Wright G; Vairappan B; Stadlbauer V; Mookerjee RP; Davies NA; Jalan R
Liver Int; 2012 Mar; 32(3):410-9. PubMed ID: 22151131
[TBL] [Abstract][Full Text] [Related]
32. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia.
Rao KV; Norenberg MD
Metab Brain Dis; 2001 Jun; 16(1-2):67-78. PubMed ID: 11726090
[TBL] [Abstract][Full Text] [Related]
33. Ammonia-mediated LTP inhibition: effects of NMDA receptor antagonists and L-carnitine.
Izumi Y; Izumi M; Matsukawa M; Funatsu M; Zorumski CF
Neurobiol Dis; 2005 Nov; 20(2):615-24. PubMed ID: 15935684
[TBL] [Abstract][Full Text] [Related]
34. Cerebral effects of ammonia in liver disease: current hypotheses.
Ott P; Vilstrup H
Metab Brain Dis; 2014 Dec; 29(4):901-11. PubMed ID: 24488230
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
36. Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.
Mondal P; Trigun SK
Metab Brain Dis; 2014 Dec; 29(4):1007-15. PubMed ID: 24807590
[TBL] [Abstract][Full Text] [Related]
37. Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy.
Bak LK; Waagepetersen HS; Sørensen M; Ott P; Vilstrup H; Keiding S; Schousboe A
Metab Brain Dis; 2013 Jun; 28(2):209-15. PubMed ID: 23371316
[TBL] [Abstract][Full Text] [Related]
38. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
Wright G; Noiret L; Olde Damink SW; Jalan R
Liver Int; 2011 Feb; 31(2):163-75. PubMed ID: 20673233
[TBL] [Abstract][Full Text] [Related]
39. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
Butterworth RF
Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia.
Mardini H; Smith FE; Record CO; Blamire AM
J Hepatol; 2011 Jun; 54(6):1154-60. PubMed ID: 21145802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
